

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

PRENYLATED CURCUMIN ANALOGUES AS MULTIPOTENT TOOLS TO TACKLE ALZHEIMER'S DISEASE

Journal:	<i>ACS Chemical Neuroscience</i>
Manuscript ID	cn-2018-00463g.R1
Manuscript Type:	Article
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Bisceglia, Federica; University of Pavia, Department of Drug Sciences Seghetti, Francesca; University of Bologna, Department of Pharmacy and Biotechnology Serra, Massimo; University of Pavia, Department of Drug Sciences Zusso, Morena; University of Padua, Department of Pharmaceutical and Pharmacological Sciences Gervasoni, Silvia; University of Milan, Department of Pharmaceutical Sciences Verga, Laura; Fondazione IRCCS Policlinico San Matteo, Pathology Vistoli, Giulio; University of Milan, Department of Pharmaceutical Sciences Lanni, Cristina; University of Pavia, Department of Drug Sciences Catanzaro, Michele; University of Pavia, Department of Drug Sciences De Lorenzi, Ersilia; University of Pavia, Department of Drug Sciences Belluti, Federica; University of Bologna, Department of Pharmacy and Biotechnology</p>

SCHOLARONE™
Manuscripts

1
2
3 **PRENYLATED CURCUMIN ANALOGUES AS MULTIPOTENT TOOLS TO TACKLE ALZHEIMER'S**
4 **DISEASE**
5
6

7 Federica Bisceglia ^a, Francesca Seghetti ^b, Massimo Serra^a, Morena Zusso ^c, Silvia Gervasoni ^d, Laura Verga ^e,
8 Giulio Vistoli ^d, Cristina Lanni ^a, Michele Catanzaro ^a, Ersilia De Lorenzi ^{*,a}, Federica Belluti ^b
9
10

11 ^a Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100, Pavia, Italy.
12
13

14 ^b Department of Pharmacy and Biotechnology, *Alma Mater Studiorum*-University of Bologna, Via Belmeloro
15 6, 40126 Bologna, Italy.
16
17

18 ^c Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Largo Meneghetti 2,
19 35131 Padua, Italy.
20
21

22 ^d Department of Pharmaceutical Sciences, University of Milan, Via Mangiagalli 25, 20133 Milan, Italy.
23
24

25 ^e Department of Molecular Medicine, Unit of Pathology, University of Pavia IRCCS Policlinico S. Matteo
26 Foundation, Via Forlanini 14, 27100, Pavia, Italy.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Alzheimer's disease is likely to be caused by copathogenic factors including aggregation of A β peptides into oligomers and fibrils, neuroinflammation and oxidative stress. To date, no effective treatments are available and because of the multifactorial nature of the disease, it emerges the need to act on different and simultaneous fronts. Despite the multiple biological activities ascribed to curcumin as neuroprotector, its poor bioavailability and toxicity limit the success in clinical outcomes. To tackle Alzheimer's disease on these aspects, the curcumin template was suitably modified and a small set of analogues was attained. In particular, derivative **1** turned out to be less toxic than curcumin. As evidenced by capillary electrophoresis and transmission electron microscopy studies, **1** proved to inhibit the formation of large toxic A β oligomers, by shifting the equilibrium towards smaller non-toxic assemblies and to limit the formation of insoluble fibrils. These findings were supported by molecular docking and steered molecular dynamics simulations which confirmed the superior capacity of **1** to bind A β structures of different complexity. Remarkably, **1** also showed *in vitro* anti-inflammatory and anti-oxidant properties. In summary, the curcumin-based analogue **1** emerged as multipotent compound worth to be further investigated and exploited in the Alzheimer's disease multi-target context.

Keywords: Alzheimer's disease; amyloid beta oligomers and fibrils; capillary electrophoresis; curcumin analogues; neuroinflammation; oxidative stress.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Alzheimer's disease (AD) is the most common form of dementia ¹ and despite impressive efforts, so far the set up of a successful anti-AD drug discovery strategy resulted extremely difficult, mainly because of the multifactorial nature of the disease ^{1,2}. In the last years, numerous AD-modifying therapeutics failed clinical trials and, to date, only five drugs mainly targeting cholinesterases have been approved by Food and Drug Administration. Compelling evidences consider extracellular amyloid-beta ($A\beta$) deposits in the brain as one of the main AD hallmarks ^{1,3,4}: they trigger microglia and astrocytes activation, which in turn results in chronic inflammation and cellular oxidative stress ^{3,5,6}. All these mechanisms, together with mitochondria and neurovascular dysfunctions, are mutually involved in a feed-forward loop, ultimately leading to progressive neurodegeneration ^{1,6}.

$A\beta$ protein includes natively disordered peptides, ranging from 36 to 43 amino acids, that are produced from the sequential metabolism of amyloid precursor protein by β - and γ -secretases ⁴; in particular, the predominant species found in plaques is the most toxic and amyloidogenic $A\beta_{1-42}$ ($A\beta_{42}$). Monomeric $A\beta_{42}$ peptide is prone to self-assembly into oligomeric species, which aggregate to form protofibrils and then mature amyloid fibrils ^{2,4}. Some well-defined $A\beta$ peptide regions are involved in the aggregation process ⁷. The glycosaminoglycan (GAGs) binding site (HHQK) assists, via a α -helix intermediate, the conformational transition of monomers from normal random coil to β -sheet structure which is characterized by an increased tendency to aggregate into dimers and oligomers ⁸. The stabilization of the soluble $A\beta$ monomers conformation, or the prevention of the α -to- β conformational transition, represent suitable strategies to avoid oligomers formation. The self recognition hydrophobic core (¹⁶KLVFFA²¹), located in the central region of $A\beta$ peptide, constitutes a nucleation site that initiates the $A\beta$ - $A\beta$ interaction ⁹. In particular, π - π stacking involving the two Phe residues may play a significant role in the self-assembly process. The emerging π - π -hypothesis suggests that drugs able to block these interactions may effectively control the amyloid diseases ¹⁰. After this primary lag step, spherical oligomers transform into larger aggregates (nucleation phase) and an equilibrium between hydrophobic and hydrophilic interactions, involving Glu²²-Gly²⁹ residues, is thought to affect this stage.

Notably, in the last 25 years attention has been shifted from amyloid fibrils to soluble prefibrillar $A\beta$ oligomers which, unlike other amyloidoses, are found to be more toxic than mature fibrils ¹¹. $A\beta_{42}$ oligomers bind to hippocampal neurons and hamper synaptic plasticity, manifested as inhibition of the long-term potentiation, which is involved in learning and memory ^{4,12}. To date, it is not clear which particular oligomeric state is mainly involved in eliciting neurotoxic effects and by which specific mechanism. Indeed, the transient and non-covalent nature makes it difficult their identification and characterization ^{2,13,14}. On the other hand, also insoluble fibril deposits are found to be neurotoxic since, being in equilibrium with oligomers, they may serve as a reservoir and catalyze oligomer formation through

1
2
3 secondary nucleation pathways. Consequently, both oligomers and fibrils represent important targets. In
4 this scenario, a multitarget approach based on the simultaneous inhibition of some relevant AD targets
5 offers promises to achieve a successful therapeutic outcome ¹⁵.

6
7
8 Curcumin (Figure 1), the primary bioactive compound found in the rhizome of *Curcuma longa*, has been
9 reported to interfere with A β aggregation and to attenuate oxidative stress and neuroinflammation ¹⁶⁻¹⁸.

10
11 The 4-hydroxy,3-methoxy-phenyl (vanillin) rings of curcumin were shown to adopt a correct position to
12 establish π - π interactions with Phe¹⁹ and Phe²⁰ residues of A β ^{19, 20}, as a result of the appropriate length and
13 flexibility of the heptatrienone central linker ^{21, 22}. In addition, the curcumin coplanar rearrangement allows
14 the intercalation between the A β fibrils, thus hampering the β -sheets assembly and in turn the fibrillation
15 pathways ²⁰. Nevertheless curcumin does not have success in clinical trials, due to its poor bioavailability
16 and possible toxic effects, mainly ascribed to the 4-hydroxy,3-methoxy substitution pattern of the two aryl
17 rings ^{21, 23}. Together with a large number of multipotent compounds such as quinones, catechols, and
18 isothiazolones, curcumin has been included among pan-assay interfering compounds (PAINS), since they
19 can display apparent bioactivity and/or interfere with assay readouts ^{23, 24}. It is not definite whether
20 compounds containing a PAINS-related sub-structure behave as reactive chemicals rather than selective
21 drugs, indeed the reactivity of a compound or other effects might be also context-dependent ²⁵. However, a
22 number of curcumin-based compounds, when properly decorated, have been shown to exert significant
23 biological activities, thus confirming the great potential of the curcumin scaffold for drug discovery. In this
24 context, the key chemical features for an A β ligand have been identified to comprise two sterically bulky
25 aromatic moieties, connected by a flexible linker of suitable length, to ensure their optimal spatial
26 arrangement ²². The resulting elongated and flat molecule demonstrated to hamper the characteristic π - π
27 stacking interactions between the aromatic residues of A β monomers, oligomers, or filaments ^{19, 20}.

28
29
30 In order to identify multipotent AD disease-modifying drug candidates ^{15, 26} with an improved biological
31 profile as compared to the reference compound curcumin, a small series of newly synthesized analogues
32 was here tested for anti-oligomeric and anti-fibrillogenic activity, while toxicity was evaluated on both
33 neuroblastoma and microglia cells. Molecular docking and steered molecular dynamics (SMD) simulations
34 were performed in order to assess the molecular recognition of the derivatives with either monomeric or
35 aggregated A β ₄₂ and to assess the stability of the corresponding complexes which are responsible for the
36 inhibitory activity. The identification of probes able to modulate A β aggregation, inflammation and
37 oxidative stress could allow to shed light into this cross-talk and represents a crucial issue in the AD drug
38 discovery scenario. Therefore, the most promising compounds in terms of anti-oligomeric and anti-
39 fibrillogenic activity were also evaluated for their anti-inflammatory and anti-oxidant properties.

40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS AND DISCUSSION

Design and synthesis of curcumin analogues. The aromatic 4-hydroxy,3-methoxy substitution patterns of curcumin (**cur**, Figure 1) were sequentially replaced with the *para*-3,3-dimethylallyloxy (4-prenyloxy), to obtain **1** as asymmetrical compound, bearing both vanillin and 4-prenyloxyphenyl functions, and **2** (Figure 1), as symmetrical counterpart in which both side rings were decorated with the 4-prenyloxy group. This moiety, found in a large number of natural products, proved to be often associated to neuroprotective effects, such as anti-inflammatory and anti-oxidant, among others ^{27, 28}. This flexible mono-unsaturated function could also impart to the molecule an increased capability to establish hydrophobic contacts with A β monomers. Furthermore, the importance of the hepta-1,4,6-trien-3-one central linker was studied by its proper simplification into a penta-1,4-dien-3-one, obtaining the corresponding compounds **3** and **4** (Figure 1). Since this structural modification has been successfully introduced in the design of curcumin derivatives with increased anti-proliferative and anti-inflammatory activities ²⁹, we wondered if the same increased activity would have been observed in AD multi-target context. Indeed, the maintenance of the carbonyl α,β -unsaturated electrophile reactive centre, together with the length of the linker (6–19 Å) and its rigidity are some of the key chemical features required to effectively inhibit amyloid aggregation ²².






Figure 1. Design strategy toward the curcumin-based analogues **1-4**. Structures of curcumin (**cur**), the newly synthesized curcuminoids (**1, 2**) and their monocarbonyl analogues (**3, 4**).

Chemistry. The synthetic route for the attainment of the target curcumin-based compounds (**1-4**) is outlined in Schemes 1 and 2. Compounds **1** and **2** were prepared by two-consecutive steps, applying the Pabon reaction ^{26, 30}. Analogues **3** and **4** were synthesized through base-catalyzed Claisen-Schmidt procedure. In the classical Pabon procedure pentane-2,4-dione was complexed with B₂O₃ in EtOAc to avoid the methylene-centred reactivity toward the Knoevenagel reaction and to favor the nucleophilic attack at the side methyl groups. The boric complex was then condensed with the suitable aldehyde and then a step-

wise addition of *n*-tributylborate and *n*-butylamine was carried out. Acidic treatment caused the dissociation of the complex, providing the desired curcumin-based analogue. This reaction has been reported to give the curcuminoid as β -keto-enol tautomer. In the classical Claisen-Schmidt aldol condensation, acetone was reacted with the appropriate aldehyde in EtOH and in the presence of a 50% KOH/H₂O solution. In details, by condensing pentane-2,4-dione or acetone with two different selected aldehydes, namely 4-hydroxy-3-methoxybenzaldehyde (vanillin) and 4-(3,3-dimethylallyloxy)benzaldehyde, a mixture of the desired compounds could be obtained, among which the asymmetrical and the two symmetrical curcuminoids, including the semi-reaction products. Consequently, obtaining the desired compounds in a good purity grade would require several chromatographic purifications. To avoid this drawback, the synthesis of asymmetric curcumin analogues **1** and **3** (Scheme 1) was performed through two sequential steps, in which the semi-synthetic intermediates were first prepared reacting pentane-2,4-dione and acetone with vanillin under the appropriate reaction condition to give **5** and **6**, respectively. Subsequently, a second reaction with 4-(3,3-dimethylallyloxy)benzaldehyde, allowed the attainment of the desired asymmetrical compounds. In order to prepare the symmetrical analogues **2** and **4** (Scheme 2) a one-pot procedure, by using a 1:2 stoichiometric ratio for the ketone and the benzaldehyde, was performed. The 4-(3,3-dimethylallyloxy)benzaldehyde (**7**) was obtained by exploiting a Williamson ether synthesis between 4-hydroxybenzaldehyde and 3,3-dimethylallylbromide in the presence of K₂CO₃ as base.



Scheme 1. Reagents and conditions: i) B(*n*-BuO)₃; ii) *n*-BuNH₂, 80 °C; iii) HCl, 80 °C; iv) KOH 50%. EtOH, rt.



Scheme 2. Reagents and conditions: i) B(*n*-BuO)₃; ii) *n*-BuNH₂, 80 °C; iii) HCl, 80 °C; iv) KOH 50%. EtOH, rt.

Cell toxicity of curcumin and analogues. In view of evaluating if the A β ₄₂ oligomers-induced toxicity is ameliorated in presence of the newly synthesized analogues (**1-4**), the intrinsic toxicity was assessed on neuroblastoma (SH-SY5Y) and microglia cells by using **cur** as reference compound. Cells were exposed to compound concentrations ranging from 1 to 50 μ M for 24 hours or from 1 to 40 μ M for 16 hours, respectively. As shown in Figure S1a), high concentrations (20-50 μ M) of all tested compounds induced a significant loss of neuroblastoma cell viability in comparison to cells exposed to culture medium only. The di-prenoxylated derivatives **2** and **4** showed a significant and comparable profile, as toxic effects were observed at 5 μ M concentration. At high concentrations (20-50 μ M), **3** considerably reduced cell viability, conversely, at concentrations ranging from 1-10 μ M it was found to be not toxic, alike **cur** and **1**.

Compound **2** exerted a similar effect on microglia cell viability, showing a cytotoxic activity from 1 μ M concentration. Interestingly, treatment of microglia with **1**, even at 20 and 40 μ M concentrations, did not significantly affect cell viability in comparison with vehicle-treated control cells, whereas the same concentrations of **cur** were cytotoxic (Figure S1b)), confirming previously published results³¹.

Inhibition of A β ₄₂ aggregation. On the basis of the amyloid hypothesis, a variety of anti-amyloid agents have been developed over the years, with the aim of interfering either with A β peptides oligomerization or fibrillogenesis or with both events^{2, 14}. Despite the efforts made, results are not yet encouraging. The assays employed in *in vitro* aggregation studies show limitations in providing simultaneous and comparable information on both fibrils and oligomers, as well as among oligomers of different size. As a consequence, it is clear that more than one technique has to be used, since a potential inhibitor of the oligomerization may not be identified by using a specific assay for fibrils¹⁴.

The evidence of fibril formation or inhibition is commonly given by well established techniques, such as transmission electron microscopy (TEM) and thioflavin T (ThT) fluorescence. Conversely, the identification and characterization of soluble A β oligomers involved in the pathological cascade are extremely challenging; indeed to date, a specific oligomeric state to target is missing^{2, 14}. In particular, the difficulties

1
2
3 in obtaining well characterized A β oligomers in solution, as well as the dynamic equilibrium among
4 oligomers which keep on aggregating during the *in vitro* experiments, represent important issues in the
5 search for modulators of fibrillogenesis³².
6
7

8 In this context, it has been demonstrated that capillary electrophoresis (CE) can play an alternative role in
9 the *in vitro* aggregation studies of A β peptides. Since it works in free solution and in the absence of
10 secondary equilibria, CE allows a real snapshot of A β while assembling into soluble oligomers inside the
11 capillary, until sample precipitation³³. The use of CE to identify agents able to interfere with A β_{42}
12 oligomerization has been pioneered by us and also reported by others³⁴⁻³⁶. Furthermore, the combination
13 of CE analysis of A β_{42} solutions in the presence of an anti-aggregating candidate with the TEM images of the
14 final precipitate, provides integrated information on the anti-oligomerization and anti-fibrillogenesis
15 activity³²⁻³⁵.
16
17
18
19
20

21 *Anti-oligomeric activity.* In this work, we exploited one of the analytical platforms recently reported by us
22 that were optimized and standardized to correlate aggregation state, structure and toxicity of A β_{42}
23 oligomers separated by CE, in view of coincubation experiments³².
24
25

26 Before carrying out any analysis of an A β_{42} sample in the presence of an inhibitor of aggregation, the setup
27 of a reproducible protocol for A β_{42} sample preparation and in turn of a reproducible CE separation of the
28 prepared oligomers are mandatory prerequisites. A β_{42} peptide aggregates and precipitates very rapidly,
29 therefore to appreciate differences in oligomer formation kinetics or to detect reduction/abrogation of
30 oligomer building-up by a coincubated compound, it is necessary to keep the assemblies in solution for a
31 suitable time window. Moreover, the toxicity of the oligomeric populations detected and separated by CE
32 has to be known, for identifying the target species of the small molecules evaluated.
33
34
35
36
37

38 In particular, for observing the effect of coincubated molecules, the least aggregating sample preparation
39 protocol was selected³⁷, as it allows a wider time window if compared with other methods³⁴⁻³⁶. Since **cur**
40 and compounds **1-4** are soluble in pure ethanol, an adjustment of the original A β_{42} sample preparation
41 protocol was necessary (see Experimental Section), to account for the percentage of ethanol in buffer when
42 coincubating the peptide and the compounds. The comparison of the CE profile and mobility values
43 reported in³² with those of A β_{42} control (i.e. in the absence of compounds) shown in Figure 2a) and Table
44 S1 (Supplementary material), demonstrate that the kinetics of formation of oligomers and all
45 electrophoretic parameters are not affected by a concentration of ethanol in buffer as high as 3.26%.
46 Therefore, precise peak identification, molecular weight range and toxicity of the separated oligomers can
47 be considered the same. Briefly, Figure 2a) shows the analysis of A β_{42} peptide injected in the CE system
48 after different elapsed times from sample solubilization (t₀): monomers and dimers (peaks 1 and 2)
49 progressively convert over time into neurotoxic aggregates larger than dodecamers (peak 3)³². At late
50 times from solubilization, large aggregates are the most abundant species, until insoluble fibrils are formed
51
52
53
54
55
56
57
58
59
60

1
2
3 and no more soluble species are detected. As small oligomers are not toxic ³², a compound is considered
4 active if it interferes with the formation of the assemblies migrating under peak 3.
5

6 All coinubation studies were carried out in triplicate and electrophoretic traces were recorded for **cur** and
7 all analogues, at different concentrations and at different elapsed times from sample redissolution.
8

9
10 Figure 2b) shows the effect on the normalized area percentage of peak 3 in the presence of a given
11 compound at the highest concentration tested (50 μ M), at a time point where, for the control sample, the
12 formation of toxic species is maximized (first bar). All compounds show some activity, although it is clear
13 that the asymmetrical hepta-1,4,6-trien-3-one-based analogue **1** turns out to be the most effective of the
14 series in suppressing the building up of toxic oligomers, followed by **cur** and then **2**, while the 1,4-dien-3-
15 one analogues **3** and **4** are remarkably less active. Complete information on many time points from
16 solubilization up to precipitation is reported in Figure S2, to appreciate how **1**, even at later times, is
17 evidently more potent than **cur**.
18
19

20
21
22
23 Based on these results, experiments have been performed at 10 μ M compound concentration, focusing the
24 attention on **cur**, **1** and **2**, both endowed with the curcuminoid scaffold. Figure S3 (as compared to Figure 2
25 b)) shows how the activity is kept, in the same order, albeit with decreasing potency. Electropherograms in
26 Figures 2 c) d) and e) easily visualize how derivative **1** (red trace) is best in suppressing the formation of
27 large toxic oligomers (peak 3). The lower anti-aggregation activity of compound **2** (blue trace) could be
28 partially ascribed at the lack of aromatic substituents capable of taking part in hydrogen bonding, which,
29 conversely, are highly conserved in most amyloid ligands of natural origin ²².
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






Figure 2. Oligomerization of $100 \mu\text{M}$ $A\beta_{42}$ in the absence or in the presence of **cur** and of compounds **1-4**. a) Electrophoretic profiles of $A\beta_{42}$ control (solubilized in 3.26% EtOH in 20 mM phosphate buffer pH 7.4, see Experimental section) at selected elapsed times from t_0 until precipitation: monitoring over time by CE. b) Anti-aggregation activity of $50 \mu\text{M}$ **cur** and compounds **1-4**: normalized area % of peak 3 at 21 days from sample redissolution as observed in control peptide and in the presence of compounds. Data are expressed as mean \pm standard deviation, for $n=3$. c-e) Comparison between electrophoretic profiles of $100 \mu\text{M}$ $A\beta_{42}$ control (black trace) and in the presence of $10 \mu\text{M}$ **cur** (green traces), **1** (red traces) and **2** (blue traces) at different elapsed times from redissolution. Electropherograms are representative of $n=3$.

Complete evaluation at decreasing concentrations down to 1 μM is reported in Figure 3. Here the observations on the reduction of the toxic large oligomers (peak 3) can be summarized as follows: i) independently on the concentration tested, the symmetrical analogue **2** only slows down the formation of toxic oligomers, that are eventually formed as abundant as they are in the control sample; ii) both **cur** and **1** show concentration-dependent activity down to 1 μM (see also Figure S3); iii) at the lowest concentration and in comparison with **cur**, not only does **1** show a more consistent reduction (nearly double) of the toxic oligomers at the end point of the analyses, but it also keeps their abundance constantly low over time.


a)



b)



c)



1
2
3 Figure 3. Anti-oligomeric effect of compounds on toxic large oligomers (peak 3) over time. Normalized area
4 percentage plot of peak 3 of 100 μM $\text{A}\beta_{42}$ control and in the presence of decreasing concentrations of: a) **cur**, b) **1**, c)
5 **2**. Data are expressed as mean \pm standard deviation, for $n=3$.
6
7

8
9 Figure 2e) also provides information on the effect that coincubation of compounds exerts on the
10 persistence in solution of non toxic monomers and dimers (earlier migrating peaks 1 and 2). In particular, it
11 is clear that dimers (peak 2) are always kept in solution for very long times, in comparison with $\text{A}\beta_{42}$ control
12 sample. This effect is consistent with the stabilization of $\text{A}\beta$ dimers induced by curcumin ²⁰. Notably, from
13 Figure S4, where the trend of the normalized area of dimers over time is reported, it can be derived that
14 this effect is markedly induced by **cur** and by its mono 4-prenyloxy-aryl substituted **1**, in a concentration-
15 dependent manner.
16
17

18
19 It can be summarized that CE data are consistent with the activity expected by virtue of the progressive
20 structural modifications performed on **1**. In particular, the further substitution of the 4-hydroxy,3-methoxy
21 group with the 4-prenyloxy (as for **2**) and the simplification of the β -keto enol function (as for **3**) result in a
22 gradual decrease of the anti-oligomeric activity, that is lowest for **4**, in which both modifications are
23 combined. The order of potency observed is **1**>**cur**>**2**>**3**>**4**.
24
25

26
27 Anti-fibrillogenic activity. Because of the intrinsic fluorescence of curcumin, ThT fluorescence assay is
28 precluded ³⁸, therefore TEM has been here employed to appreciate the effect of **cur** and **1-4** on fibril
29 formation, fibril morphology and fibril density. Conclusions are drawn on data obtained for three
30 independent samples each one measured in duplicate.
31
32

33
34 As shown in Figure 4, $\text{A}\beta_{42}$ peptide alone contains fibrils already at early stages from solubilization (24
35 hours), although, as explained in ³², these are not injected in the capillary of the CE system. Conversely to
36 the control peptide and already after 24 hours, $\text{A}\beta_{42}$ samples coincubated with **cur** or **1** contain amorphous
37 aggregates only. The absence of amyloid fibrils is kept at later stages of oligomerization (after 21 days). This
38 evidence can be correlated with the anti-oligomeric activity induced by both compounds relative to large
39 oligomers (Figure S2, 21 days) and consistently with the persistence in solution of dimers (Figure 2 e)).
40
41

42
43 The sample containing **cur** eventually precipitates into dense amyloid fibrils. This is not overly surprising, as
44 also recent reports suggested that curcumin only inhibits oligomerization while promoting fibrillization ^{39, 40};
45 despite a growing evidence on the anti-amyloid effect of curcumin, the exact mechanism of action is still
46 debated.
47
48

49
50 Contrary to samples coincubated with **cur**, only sporadic fibrils are detected in precipitated samples of $\text{A}\beta_{42}$
51 in the presence of derivative **1**. Surprisingly, compound **2** abrogates the formation of the fibrils observed
52 after 24 hours, as only amorphous granular assemblies are detected at sample precipitation. In accordance
53 with the poor anti-oligomeric activity, both monocarbonyl derivatives (**3** and **4**) lead to amyloid fibrils
54 already after 24 hours and as end products of the aggregation (Figure 4).
55
56
57
58
59
60




Figure 4. TEM images of $A\beta_{42}$ control peptide (100 μ M) and 100 μ M $A\beta_{42}$ coincubated with 50 μ M **cur** and **1-4** analyzed at different times from redissolution. Scale bar=100nm. 60000x. n=3.

Modeling studies. Docking simulations were carried out to corroborate the effects of the curcumin-based analogues on $A\beta_{42}$ aggregation process and to elucidate by which specific interactions with $A\beta$ residues the tested compounds are able to modify it. Even though the $A\beta_{42}$ peptide shows a marked flexibility and can assume almost all secondary motifs, docking simulations were focused on the peptide in its alpha-helix form because this is the only available resolved structure.

Figures 5 a) b) and c) show the best complexes obtained for **cur**, **1** and **2** with the monomeric $A\beta_{42}$ peptide. As expected, the ligands approach the amyloid region corresponding to the above mentioned $^{16}KLVFFA^{21}$ sequence which is well-known to be involved in ligand recognition. In the computed complexes, the curcumin analogues assume slightly bent conformations which are in line with the curcumin geometries found in the resolved structures. For instance, the curcumin molecule included in the resolved complex with human transthyretin (PDB Id: 4PMF) shows an angle, as defined by the central carbonyl and the two aromatic rings, of 107.87 while, in the here generated complex, the same angle of **cur** is equal to 106.99 (see Figure 5a). Moreover and in all considered complexes, the β -keto-enol central core elicits H-bonds with Glu²² and Ser²⁶, while a ligand phenyl ring stabilizes a clear π - π stacking contact with Phe¹⁹. The other interactions stabilized by the phenyl moieties depend on the polarity of the substituents. Thus, **cur**, through a side vanillin group, elicits H-bonds with Gln¹⁵ and Asn²⁷, while asymmetrical analogue **1** retains the same polar contacts and, through its prenyloxy function, adds clear hydrophobic interactions with Ile³¹. The diprenoxylated **2** loses the H-bond with Gln¹⁵ and adds apolar contacts with Val¹⁸. Both monocarbonyl analogues (**3** and **4**) lose the key polar interactions with Glu²² (complexes not shown). As depicted in Figure S5, the complexes as computed by considering more extended amyloid structures show comparable ligand poses even though the involvement of more amyloid segments increases the number of interacting residues especially concerning the hydrophobic residues.

1
2
3 While contacting the same well-known amyloid region, Figure 5 d) e) and f) show that the simulated ligands
4 assume different poses when interacting with the fibril structures. In particular, the ligands assume rather
5 extended geometries by which they contact six different amyloid segments. As seen for **1**, the ligands
6 contact the same residues of all involved segments: in detail, they elicit i) extended hydrophobic contacts
7 with six Leu¹⁸ residues which contact both phenyl ring and alkyl chains and ii) extended H-bonds with six
8 Lys¹⁶ residues, which approach both the β -keto-enol central core and the substituents on phenyl rings. Not
9 to mention that these protonated residues can also stabilize charge-transfer interactions with the phenyl
10 rings. Taken together, one may observe that, while the ligands assume comparable poses in all simulated
11 amyloid structures, the relevance of hydrophobic contacts increases when increasing the complexity of the
12 simulated amyloid structure and finds its maximum expression with the fibril structure where the ligands
13 are supported by a basis completely composed of apolar residues. These observations suggest that the
14 interaction with simple amyloid structures are enhanced by a fine balance between polar and apolar
15 contacts as seen for **1** in the monomeric protein, while the interaction with complex amyloid structures
16 appears to be strongly governed by hydrophobic contacts.

17
18 The described molecular docking results find encouraging validations by SMD simulations involving A β ₄₂
19 tetramers and fibrils and comparing **1** and **2** with **cur**. In these simulations the ligand is forced to unbound
20 from the A β ₄₂ structures and the required pulling force is monitored during the time. As compiled in Table
21 S2, each simulated ligand is thus characterized by the time required to unbound the ligand (i.e. until the
22 monitored force is 0 pN) as well as by the force mean required for unbinding. A third relevant parameter is
23 the AUC value of the plot limited to the residence time which accounts for both the total force and required
24 time. With regards to A β ₄₂ tetramers, Table S2 shows that the most polar **cur** compound requires an initial
25 marked force to break its key polar interactions (as reflected in the highest force mean) but then is unable
26 to prolong its binding and indeed it shows a residence time and AUC values clearly lower than **1** and **2**.
27 These results confirm that only a proper balance between polar and hydrophobic interactions is able to
28 increase the stability of the complex with A β ₄₂ oligomers over the time. In contrast and when simulating the
29 fibrils, the ligands reveal rather similar values in all reported parameters. This observation may indicate that
30 the ligands are here similarly governed by the sole hydrophobic contacts and indeed the most apolar
31 compound (**2**) shows the best force mean and AUC value.

32
33 All proposed compounds were submitted to SwissADME online web-server (<http://www.swissadme.ch>) and
34 resulted completely devoid of PAINS alerts with a predicted pharmacokinetic profile roughly comparable
35 with that of the parent compound (results not shown).
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5. Main interactions stabilizing the putative complexes with monomeric Aβ₄₂ for a) **cur**, b) **1** and c) **2**, and with the amyloid fibril structure for d) **cur**, e) **1** and f) **2**.

Evaluation of anti-inflammatory properties. The prenylation of aromatic natural products results in derivatives with an improved pharmacological profile when compared with not-prenylated compounds and prenylated natural compounds proved to be useful for the treatment of cancer and inflammation²⁷. As this latter represents an important pathological condition in AD^{3, 4}, the functionalization of **cur** by the introduction of a prenyl function could enhance the anti-inflammatory potential.

Thus, the most promising compound **1** in terms of anti-oligomeric and anti-fibrillogenic activity, was selected to be tested for its anti-inflammatory properties, in comparison to **cur**. Lipopolysaccharide (LPS) is the major component of the outer membrane of gram-negative bacteria and a potent immune activator of a variety of mammalian cell types, including microglia. Inhibition of LPS-induced release of the pro-inflammatory cytokines IL-1β and TNF-α by microglia was examined to assess the anti-inflammatory effects of analogue **1** and **cur**. Microglia cells were exposed to non-cytotoxic concentrations of test compounds for 1 hour and then stimulated with LPS for 16 hours to induce an inflammatory response. In unstimulated cells low or undetectable amounts of IL-1β and TNF-α were released and these basal levels remained unchanged after treatment with the tested compounds (white bars, Figure 6). As expected, LPS stimulation induced an increased release of IL-1β and TNF-α (taken as 100%). Not only was this effect significantly suppressed by

cur, as we previously showed^{31, 41}, but also by its prenylated analogue **1**, starting from the concentration of 5 μM .





Figure 6. Effects of **cur** and analogue **1** on cytokine release from LPS-stimulated cortical microglia cells. a) IL-1 β and b) TNF- α release. Data are mean \pm SEM (standard error of mean) (n=3). * p<0.05, ** p<0.01 and *** p<0.001 vs LPS-stimulated cultures, Kruskal-Wallis followed by *post-hoc* Dunn's test.

Evaluation of anti-oxidant properties. In addition to the anti-inflammatory activity, we then investigated the potential of compounds **1** and **2** as antioxidants. We evaluated in SH-SY5Y neuroblastoma cells their scavenger ability when co-incubated with H₂O₂, using **cur** as reference. In comparison to untreated cells, (grey line, Figure 7a)), the intracellular DCFH-fluorescence intensity in H₂O₂-treated cells significantly increased (black line, Figure 7a)). Treatment with **cur** and compounds **1** and **2** reduced H₂O₂-induced intracellular ROS production, albeit to a different extent. At any time tested, **cur** showed the strongest scavenger activity when compared to analogues **1** and **2**. In particular, the presence of both vanillin moieties (as for **cur**) appears to be important for this anti-oxidant activity. Compound **2**, lacking 4-hydroxy,3-methoxy group on both aromatic rings, was less effective than compound **1**, where one of the two vanillin functions of curcumin is preserved.

Further studies were carried out on the mechanism of action of **1** and **2** on the Nrf2 cellular pathway, for investigating their ability to modulate the expression of the Nrf2 transcription factor⁴². Recent evidence further showed that Nrf2 activation suppresses inflammation through redox control⁴³. Therefore, we investigated the activation of Nrf2 pathway by analyzing its translocation into nucleus. A concentration of 5 μM of **cur** and **1** induced Nrf2 nuclear translocation, whereas **2** did not show to be an Nrf2-inducer. The asymmetrical analogue **1**, at the concentration of 10 μM , did not produce statistically significant results in our experimental setting, although we could assume an increasing trend as compared to control (Figure 7 b)).

These data suggest that **1** may modulate anti-oxidant response by acting through different pathways, besides Nrf2 activation. Evidence from literature supports the ability of different natural products, including polyphenols in general, to interact with selected miRNAs, thus targeting multiple genes and showing pleiotropic activity⁴⁴. Hence, the differential Nrf2 activation by 10 μM **1** may be putatively related to the modulation of the levels of certain miRNAs associated with the Nrf2 signaling pathway. On the basis of these observations, the investigation of miRNA modulation could potentially be important and will be next further evaluated to better understand the underlying anti-oxidant mechanism of natural products and their derivatives.

a)



b)




Figure 7. Anti-oxidant activity of **cur** and analogues **1** and **2**. a) Reduction of H_2O_2 -induced intracellular ROS production: fluorescence intensity for all compounds is significant at any time from 30 to 270 min with $p < 0.001$ vs H_2O_2 , with exception of compound **2** at the concentration of 5 μM . For compound **2** the significance is as follows: $p < 0.05$ at 90 min; $p < 0.01$ at 120 min and 270 min; $p < 0.001$ at 150, 180, 210 and 240 min. Dunnett's multiple comparison test; b) Activation of Nrf2 pathway: SH-SY5H cells were treated for 3 hours with compounds. Results are shown as ratio Nrf2/lamin \pm SEM; * $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$ versus control; Dunnett's multiple comparison test.

CONCLUSIONS

The curcumin scaffold was rationally modified and a small set of structurally related compounds was obtained and tested against $A\beta_{42}$ oligomer and fibril formation, inflammation and oxidative stress, i.e. copathogenic factors related to AD. To this aim, derivatives were obtained in which i) a prenyloxy function was introduced as substituent in one or both the **cur** side aryl functions, and ii) the **cur** keto-enol central linker was simplified. Two couples of analogues **1-2**, and **3-4**, respectively were obtained.

The new compounds were firstly evaluated for their anti-amyloid effects, leading to identify **cur** and analogue **1**, both endowed with the hepta-trien-3-one linker, as the most effective agents in slowing down the formation of toxic $A\beta$ oligomers. Interestingly, CE and TEM analyses showed how **1** potently inhibits oligomers building up and, contrary to **cur**, it does not lead to the formation of a dense network of fibrils. Due to its remarkably lower toxicity on microglia cells if compared to **2** and even to **cur**, analogue **1** was then selected to investigate its anti-inflammatory effect on microglia activation. In particular, at 5 μM concentration, a suppression of pro-inflammatory cytokines release was detected. This analogue also showed an anti-oxidant potential, with particular reference to the capability to induce, at 5 μM , Nrf2 nuclear translocation. By contrast, the symmetrical curcuminoid **2**, in comparison to **1**, showed a remarkably weaker anti-oxidant activity and a lower efficacy in contrasting oligomer formation. Notably, fibrils were not observed in presence of compound **2** and this suggests that the two prenyloxy substituents may serve as β -sheet breakers by intercalating in the amyloid fibrillar core. The anti-amyloid effects of **1** and **2**, compared to those of **cur**, were evidently corroborated by molecular docking and SMD simulations

1
2
3 which revealed the growing role of the hydrophobic interactions when simulating A β structures of
4 increasing complexity. The simplified counterparts **3** and **4** failed to block both the formation of large A β
5 assemblies and the deposition of fibrils.
6
7

8 Taken together, these data underlined the pivotal role of the curcumin scaffold in eliciting anti-
9 amilodogenic effects, in particular when both the 4-hydroxy,3-methoxy and prenyloxy aryl substitution
10 patterns are present. Indeed, among the newly synthesized compounds, **1** turned out to be a very
11 promising anti-AD tool, endowed with a better biological profile with respect to **cur**. Due to its multipotent
12 behaviour it could be a lead compound, worthy further optimization to obtain effective AD-modifying drug
13 candidates.
14
15
16
17
18
19

20 EXPERIMENTAL SECTION

21
22
23 **Chemicals and Materials.** Synthetic A β_{42} was purchased from Bachem (Bubendorf, Switzerland) as
24 lyophilized powder and stored at -20°C. 1,1,1,3,3,3-Hexafluoropropan-2-ol (HFIP), acetonitrile (ACN),
25 dimethylsulfoxide (DMSO) and sodium carbonate (Na₂CO₃) were from Sigma-Aldrich (St. Louis, MO, USA).
26 Ethanol 96° was supplied by Carlo Erba (Cornaredo, Italy). Sodium hydroxide (NaOH) and sodium dodecyl
27 sulphate (SDS) were provided by Merck (Darmstadt, Germany). Na₂HPO₄ and NaH₂PO₄, supplied by Sigma-
28 Aldrich, were used for the preparation of the background electrolyte (BGE) in the CE analyses. BGE
29 solutions were prepared daily using Millipore Direct-Q™ deionized water (Bedford, MA, USA) and filtered
30 on 0.45 μ m Sartorius membrane filters (Göttingen, Germany). Uncoated fused-silica capillary was from
31 Polymicro Technologies (Phoenix, AZ, USA).
32
33

34 All cell culture reagents, culture medium and chemicals were purchased from Sigma-Aldrich.

35 Curcumin was purchased from Sigma Aldrich (analytical standard, purity \geq 98%).

36 All samples containing curcumin and curcumin-derivatives were kept protected from light throughout all
37 experiments.
38
39

40
41
42 **Chemistry. General Procedures.** Starting materials, unless otherwise specified in the Experimental Section,
43 were used as high-grade commercial products. Solvents were of analytical grade. Melting points were
44 determined in open glass capillaries, using a Büchi apparatus and are uncorrected. ¹H-NMR and ¹³C-NMR
45 spectra were recorded on Varian INOVA spectrometer operating at 400 MHz. Chemical shifts are reported
46 as parts per million (ppm δ value). Standard abbreviations indicating spin multiplicities are given as follows:
47 s (singlet), d (doublet), dd (doublet of doublet), t (triplet), br (broad), q (quartet) or m (multiplet). High-
48 resolution mass spectra (HRMS) were acquired with an LTQ Orbitrap XL instrument (Thermo Fisher
49 Scientific, Rodano, Milano. Resolution was set at 30000 (FWHM at 400 m/z) and scan range was 250-1000
50 m/z with a target of 5 \times 10⁵ ions per scan. Instrument control and data analysis/elaboration were provided
51
52
53
54
55
56
57
58
59
60

1
2
3 by the software Xcalibur (version 2.07, ThermoFisher Scientific, Rodano, MI, Italy). Chromatographic
4 separations were performed on silica gel columns using the flash method (Kieselgel 40, 0.040-0.063 mm,
5 Merck). Reactions were followed by thin layer chromatography (TLC) on precoated silica gel plates (Merck
6 Silica Gel 60 F254) and then visualized with a UV lamp. Purities of all tested compounds used in the
7 biological assays were determined by HPLC using the area percentage method on the UV trace recorded at
8 254 nm. The analyses were performed under reversed-phase conditions on a Phenomenex Luna 5 μ m C18
9 column (150 \times 4.60 mm), by using a ternary mixture of 0.1 % H₃PO₄/MeCN/MeOH (40:40:20, v/v) as mobile
10 phase, flow rate: 0.7 mL / min. A liquid chromatograph PU-1587 UV model equipped with a 20 μ L loop
11 valve (Jasco Europe, Italy) was employed. All compounds were found to have >95% purity, as confirmed by
12 NMR spectra (see Supplementary material). Compounds were named using Chem-BioDraw Ultra 14.0
13 IUPAC name algorithm developed by CambridgeSoft Corporation.
14
15
16
17
18
19
20
21

22 **4-(3,3-dimethylallyloxy)benzaldehyde (7)**. 4-hydroxybenzaldehyde (1.00 g, 8.19 mmol) and 3,3-
23 dimethylallyl bromide (1.14 mL, 9.83 mmol) were allowed to react according to the general procedure of
24 the Williamson reaction for 8 h to give the crude product that was purified by crystallization from PE;
25 yellow oil, 83 % yield. ¹H-NMR (400 MHz, CDCl₃): δ 1.76 (s, 3H, CH₃), 1.81 (s, 3H, CH₃), 4.60 (d, 2H, J = 6.8 Hz,
26 OCH₂), 5.45 (t, 1H, J = 6.8 Hz, CH=), 7.00 (d, 2H, J = 8.8 Hz, H-3' and H-5'), 7.83 (d, 2H, J = 8.8 Hz, H-2' and H-
27 6'), 9.88 (s, 1H, CHO).
28
29
30
31
32

33 **Pabon reaction: general procedure for the synthesis of compounds 1, 2, and 5**. To a stirred solution of
34 pentane-2,4-dione (1.00 mmol) in EtOAc (1.0 mL), B₂O₃ (1.0 molar equiv) was added, and the suspension
35 was stirred for 30 min at 80 °C before addition of a solution of the appropriate aldehyde/s, (0.9 molar equiv
36 for monoaryl or 1.8 molar equiv for bi-aryl curcumin derivatives), tri-*n*-butyl borate (2.0 molar equiv for
37 monoaryl or 4.0 molar equiv for bi-aryl curcumin derivatives), in EtOAc (0.5 mL). The reaction mixture was
38 stirred at 80 °C for 30 min, then a solution of *n*-butylamine (0.4 molar equiv in 1.0 mL of EtOAc) was
39 added over a period of 15 min. The mixture was heated to 80 °C for 8 h and then, after cooling to r.t., it was
40 acidified with 0.5 N HCl (30 mL) and then stirred at 80 °C for 30 min. The organic phase was separated and
41 the aqueous layer was extracted with EtOAc (3 \times 10 mL). The combined organic layers were sequentially
42 washed with saturated aqueous NaHCO₃ and brine, dried over Na₂SO₄, filtered, and concentrated under
43 reduced pressure. The crude residue was purified by flash column chromatography using a mixture of
44 petroleum ether / ethyl acetate (PE / EtOAc) as eluent, followed by crystallization from suitable solvent.
45
46
47
48
49
50
51
52

53 **3Z,5E-4-hydroxy-6-(4-hydroxy-3-methoxyphenyl)hexa-3,5-dien-2-one (5)**²⁶. Reaction of pentane-2,4-dione
54 (0.50 g, 5.00 mmol), B₂O₃ (0.45 g, 5.00 mmol), and vanillin (0.69 g, 4.5 mmol), in EtOAc (7.5 mL), gave a
55 crude product that was purified by flash chromatography (PE / EtOAc, 9.75:0.25), yellow powder, 55% yield,
56 mp 144-146 °C (EtOH). ¹H NMR (400 MHz, CDCl₃): δ 2.16 (s, 3H, CH₃), 3.94 (s, 3H, OCH₃), 5.40 (br, 1H, OH),
57
58
59
60

5.63 (s, 1H, keto-enol-CH), 6.33 (d, $J = 16.0$ Hz, 1H, CH=CH), 6.92 (d, $J = 8.0$ Hz, 1H, H-5), 7.02 (d, $J = 1.8$ Hz, 1H, H-2), 7.09 (dd, $J = 1.8, 8.0$ Hz, 1H, H-6), 7.53 (d, $J = 16.0$ Hz, 1H, CH=CH).

(1E,4Z,6E)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-((3-methylbut-2-en-1-yl)oxy)phenyl)hepta-1,4,6-trien-3-one (1). Reaction of intermediate **5** (0.23 g, 1.00 mmol) and **7** (0.17 g, 0.9 mmol) gave a crude product that was purified by flash chromatography (PE/EtOAc, 8.5:1.5) and further crystallization from EtOH affording **1** as orange solid, 41 % yield, mp 144-146 °C. $^1\text{H-NMR}$ (CDCl_3): δ 1.77 (s, 3H, CH_3), 1.82 (s, 3H, CH_3), 3.96 (s, 3H, OCH_3), 4.56 (d, $J = 6.8$ Hz, 2H, OCH_2), 5.50 (t, $J = 6.8$ Hz, 1H, CH=C), 5.80 (s, 1H, keto-enol-CH), 5.85 (br s, 1H, OH), 6.49 (d, $J = 15.6$ Hz, 1H, CH=CH), 6.50 (d, $J = 15.6$ Hz, 1H, CH=CH), 6.94 (d, $J = 8.0$ Hz, 2H, H-3' and H-5'), 6.95 (d, $J = 8.0$ Hz, 1H, H-5), 7.07 (s, 1H, H-2), 7.13 (d, $J = 8.0$ Hz, 1H, H-6), 7.51 (d, $J = 8.8$ Hz, 2H, H-2' and H-6'), 7.60 (d, $J = 15.6$ Hz, 1H, CH=CH), 7.63 (d, $J = 15.6$ Hz, 1H, CH=CH). $^{13}\text{C-NMR}$ (CDCl_3): δ 18.4, 26.0, 56.1, 65.1, 101.4, 109.7, 115.0, 115.2 (2C), 119.4, 122.0, 121.9, 123.1, 127.8, 127.9, 129.9 (2C), 138.9, 140.4, 140.6, 146.9, 148.0, 160.8, 183.4, 183.5. HRMS (ESI) calcd. for $\text{C}_{25}\text{H}_{27}\text{O}_5$ $^{14+}$ 407.18530; found 407.18533 ($\Delta = 0.1$ ppm).

(1E,4Z,6E)-5-hydroxy-1,7-bis(4-((3-methylbut-2-en-1-yl)oxy)phenyl)hepta-1,4,6-trien-3-one (2). Reaction of pentane-2,4-dione (0.15 mL, 1.46 mmol) and **7** (0.5 g, 2.63 mmol) gave the crude product that was purified by flash chromatography (PE/EtOAc, 9.75:0.25) and further crystallization from EtOH, affording **2** as yellow solid, 45 % yield, mp 165-167 °C. $^1\text{H-NMR}$ (400 MHz, CDCl_3): δ 1.76 (s, 6H, CH_3), 1.81 (s, 6H, CH_3), 4.56 (d, $J = 6.8$ Hz, 4H, OCH_2), 5.50 (t, $J = 6.8$ Hz, 2H, CH=C), 5.78 (s, 1H, keto-enol-CH), 6.51 (d, $J = 15.6$ Hz, 2H, CH=CH), 6.93 (d, $J = 8.4$ Hz, 4H, H-3' and H-5'), 7.51 (d, $J = 8.4$ Hz, 4H, H-2' and H-6'), 7.63 (d, $J = 15.6$ Hz, 2H, CH=CH). $^{13}\text{C-NMR}$ (100 MHz, CDCl_3): δ 18.4 (2C), 26.0 (2C), 65.1 (2C), 101.5, 115.2 (4C), 119.4 (2C), 121.9 (2C), 127.9 (2C), 129.9 (4C), 138.8 (2C), 140.3 (2), 160.8 (2C), 183.5 (2C). HRMS (ESI) calcd. for $\text{C}_{29}\text{H}_{33}\text{O}_4$ $^{14+}$ 445.23734; found 445.23553 ($\Delta = -1.6$ ppm).

Claisen-Schmidt Reaction: general procedure for the synthesis of compounds 3, 4, and 6. To a solution of ketone (1.0 mmol) and the selected aldehyde (1.1 mmol or 2.2 mmol) in EtOH (10 mL), a KOH aqueous solution (50% p/v, 1 mL) was added dropwise. The reaction mixture was stirred overnight at room temperature, then diluted with H_2O and acidified with aqueous 6N HCl. The separated solid was collected by *vacuum* filtration and purified by flash chromatography or by crystallization.

(E)-4-(4-hydroxy-3-methoxyphenyl)but-3-en-2-one (6). Reaction of propan-2-one (0.25 g, 5.00 mmol), vanillin (0.98 g, 5.5 mmol), in EtOH (5.0 mL), gave a crude product that was purified by crystallization from EtOH to give **6** as white solid, 75% yield, mp 95-98 °C. $^1\text{H-NMR}$ (400 MHz, CDCl_3): δ 2.37 (s, 3H, CH_3), 3.94 (s, 3H, OCH_3), 5.99 (br, 1H, OH), 6.59 (d, $J = 16.0$ Hz, 1H, CH=CH), 6.94 (d, $J = 8.4$ Hz, 1H, H-6), 7.06 (d, $J = 2.0$ Hz, 1H, H-2), 7.09 (dd, $J = 2.0, 8.4$ Hz, 1H, H-5), 7.46 (d, $J = 16.0$ Hz, 1H, CH=CH).

(1E,4E)-1-(4-hydroxy-3-methoxyphenyl)-5-(4-((3-methylbut-2-en-1-yl)oxy)phenyl)penta-1,4-dien-3-one (3). Reaction of intermediate **6** (0.19 g, 1.00 mmol) and **7** (0.21 g, 1.1 mmol), gave the crude product that

was purified by flash chromatography (PE/EtOAc, 7:3) and further crystallization from EtOH, affording **3** as pale orange solid 85% yield, mp 101-113 °C. ¹H NMR (400 MHz, CDCl₃): δ 1.77 (s, 3H, CH₃), 1.82 (s, 3H, CH₃), 3.96 (s, 3H, OCH₃), 4.56 (d, *J* = 6.8 Hz, 2H, OCH₂), 5.50 (t, *J* = 6.8 Hz, 1H, CH=C), 5.97 (br, 1H, OH), 6.91-7.00 (m, 5H, CH=CH, H-5, H-3', H-5'), 7.12 (d, *J* = 1.6 Hz, 1H, H-2), 7.18 (dd, *J* = 2.0, 8.4 Hz, 1H, H-6), 7.57 (d, *J* = 8.8 Hz, 2H, H-2' and H-6'), 7.67 (d, *J* = 15.2 Hz, 1H, CH=CH), 7.71 (d, *J* = 15.2 Hz, 1H, CH=CH). ¹³C NMR (100 MHz, CDCl₃): δ 18.4, 26.0, 56.1, 65.1, 109.9, 115.0, 115.2 (2C), 119.3, 123.2, 123.5, 123.8, 127.6, 130.2 (2C), 138.9, 142.9, 143.2, 147.0, 148.3, 161.1, 189.0. HRMS (ESI) calcd. for C₂₃H₂₅O₄¹⁴⁺ 365.17474; found 365.17471 (Δ = -0.1 ppm).

(1E,4E)-1,5-bis(4-((3-methylbut-2-en-1-yl)oxy)phenyl)penta-1,4-dien-3-one (4)⁴⁵. Reaction of propan-2-one (0.25 g, 5.00 mmol), vanillin (1.95 g, 11.0 mmol), in EtOH (5.0 mL), gave a crude product that was purified by crystallization from EtOH to give **4** as yellow solid, 87% yield, mp 74-76 °C. ¹H NMR (400 MHz, CDCl₃): δ 1.77 (s, 6H, CH₃), 1.82 (s, 6H, CH₃), 4.56 (d, *J* = 6.8 Hz, 4H, OCH₂), 5.50 (t, *J* = 6.8 Hz, 2H, CH=C), 6.94-6.98 (m, 6H, CH=CH, H-3, H-5), 7.56 (d, *J* = 8.8 Hz, 4H, H-2 and H-6), 7.70 (d, *J* = 16.0 Hz, 2H, CH=). ¹³C NMR (CDCl₃) δ 18.3 (2C), 25.9 (2C), 65.0 (2C), 115.2 (4C), 119.3 (2C), 123.5 (2C), 127.6 (2C), 130.1 (4C), 138.8 (2C), 142.8 (2C), 161.0 (2C), 189.0. HRMS (ESI) calcd. for C₂₇H₃₁O₃¹⁴⁺ 403.22677; found 403.22675 (Δ = 0.0 ppm).

Capillary electrophoresis. Aβ₄₂ peptide was solubilized by following the procedure described in³⁷. Briefly, lyophilized Aβ₄₂ was dissolved in HFIP and then the solvent was left to evaporate after an appropriate incubation time. The Aβ₄₂ aliquots were redissolved in a basic mixture (ACN/300 μM Na₂CO₃/250 mM NaOH, 48.3:48.3:3.4, v/v/v) to obtain 500 μM Aβ₄₂. This solution was then diluted to the operative concentration (100 μM Aβ₄₂ control peptide) with 20 mM phosphate buffer pH=7.4, with or without small molecules.

Stock solutions of **cur** and of curcumin-based analogues (1.53 mM) were prepared in pure ethanol.

For co-incubation studies, 500 μM Aβ₄₂ peptide (in the basic mixture) was resuspended in an appropriately diluted compound solution, so as to keep the peptide concentration at 100 μM and obtain different peptide/compound ratios: 1:100, 1:10, 1:4, 1:2 for **cur** and **1**; 1:10, 1:4, 1:2 for **2** and 1:2 for **3** and **4**. The final percentage of ethanol was equal or lower than 3.26%.

The aggregation process of Aβ₄₂ in the presence or not of **cur** and of curcumin-based analogues was monitored by an Agilent Technologies 3D CE system with built-in diode-array detector (Waldbronn, Germany), following the analytical method reported in³². For the separation, a fused silica capillary (Polymicro Technologies, Phoenix, AZ, USA) of 33 cm (24.5 cm, effective length) was employed. The background electrolyte (BGE, 80 mM Na₂HPO₄/NaH₂PO₄ (pH 7.4)) was prepared daily and filtered on 0.45 μm membrane filters. The injection of the samples was carried out by applying a pressure of 30 mbar for 3 s. The capillary was thermostatted with circulating air at 25°C and separations were carried out at 12 kV

(operative current: 75–78 μA) with the anode at the sample injection end. The acquisition wavelength was 200 nm. Oligomeric species were identified on the basis of effective mobilities (μ_{eff}), which are calculated by subtracting the contribute of the electrosmotic flow (μ_{EOF}) from the apparent mobility (μ_{app}). Electrosmotic flow is measured as a perturbation of the baseline due to the sample solvent mixture. Semiquantitative analyses were performed based on the normalized area % ³².

Transmission Electron Microscopy. Amyloid fibril identification was carried out by using a JEOL JEM 1400-Plus electron microscope (Peabody, MA, USA) operating at 80 kV. When no more peaks are detected by CE, precipitated samples were prepared as follows: $\text{A}\beta_{42}$ sample suspensions with or without **cur** and analogues **1-4** were diluted at 10 μM with 20 mM $\text{Na}_2\text{HPO}_4/\text{NaH}_2\text{PO}_4$ and then 10 μL of diluted suspensions were left to sediment on carbon-coated Formvar nickel grids (200 mesh) (Electron Microscopy Sciences, Washington, PA, USA). After 15 minutes the excess of sample was drained off by means of a filter paper. The negative staining was performed with 10 μL of 2%w/v uranyl acetate solution (Electron Microscopy Sciences).

Docking studies. In order to rationalize the different activity of curcumin and the here proposed derivatives, molecular docking simulations were performed involving the resolved $\text{A}\beta_{42}$ peptide (PDB Id: 1IYT), which was simulated in its monomeric, dimeric and tetrameric forms. Calculations also included the resolved amyloid fibril (PDB Id: 2MXU). The ligands were simulated in their keto-enolic form and their conformational space was explored by combining MonteCarlo simulations and PM7-based semi-empirical minimizations as previously described ⁴⁶. In detail, the amyloid monomer was minimized by keeping fixed the backbone atoms to preserve the resolved folding and utilized to build the corresponding dimer by following the computational procedure as described by Rao and co-workers ⁴⁷. Briefly, two optimized monomers were initially aligned at an average distance between the backbone atoms of the two monomers of about 10 Å and then the monomers were progressively approached and optimized to reach a final average distance of about 5 Å. The resolved fibril structure underwent the same refinement protocol as described for monomer before docking simulations. Thus, SMD simulations involved $\text{A}\beta_{42}$ in its monomeric, dimeric and fibril forms and were performed by using PLANTS and by including the entire amyloid structure in its searches ⁴⁸. For each simulated ligand, 20 poses were generated and ranked by ChemPLP score with a speed equal to 1. All obtained poses were then minimized. The best dimeric complexes were finally utilized to generate the corresponding tetramers by docking on them a second dimer structure. Such a dimer-dimer docking was performed using PatchDock by adopting its default parameters and the so generated 20 docking results were finally refined by FireDock ⁴⁹. The so produced best tetrameric complexes were finally minimized by keeping fixed the backbone atoms. The computed tetrameric and fibril complexes for **1**, **2** and **cur** were then neutralized and inserted into a 80 Å side box of

1
2
3 water. After a preliminary minimization, the systems underwent 3 ns SMD simulations with the same
4 characteristics as described in ⁵⁰.

6
7 **Inhibition of cytokines release.** All animal-related procedures complied with the ARRIVE guidelines and
8 were performed in accordance with EU guidelines for the care and use of laboratory animals and those of
9 the Italian Ministry of Health (D.Lg. 26/2014) and were approved by the Institutional Review Board for
10 Animal Research (Organismo Preposto al Benessere Animale, OPBA) of the University of Padua and by the
11 Italian Ministry of Health (Protocol number 958/2016-PR). One-day old Sprague-Dawley rat pups (CD strain)
12 were rapidly decapitated, minimizing suffering, discomfort or stress. Primary microglia cells were isolated
13 from mixed glial cell cultures prepared from cerebral cortex, as previously described ⁵¹. Briefly, upon
14 reaching confluence (7–10 days after isolation) microglia adhering to the astroglial monolayer were
15 dislodged by shaking (200 r.p.m. for 1 h at 37°C), resuspended in high-glucose Dulbecco's Modified Eagle's
16 Medium (DMEM) supplemented with 2 mM L-glutamine, 10% heat-inactivated fetal bovine serum (FBS),
17 100 U/mL penicillin, 100 µg/mL streptomycin and 50 µg/mL gentamicin and plated on uncoated plastic
18 wells at a density of 1.25×10^5 cells/cm². Cells were allowed to adhere for 45 min and then washed to
19 remove non-adhering cells. After a 24 h incubation period, the medium was replaced with serum-free
20 medium containing the agents under study. Purity of the cultures was confirmed by immunocytochemistry
21 using a primary polyclonal antibody against ionized calcium binding adaptor molecule 1 (Iba1, 1:800, Wako
22 Chemicals USA Inc., Richmond, VA, USA). Ninety-seven per cent of the cells were Iba1 immunopositive.
23 Cells were maintained at 37°C in a humidified atmosphere containing 5% CO₂/95% air.

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Microglia were pre-treated for 1 hour with non-cytotoxic concentrations of **cur** and **1** and then stimulated
with 100 ng/mL Ultra-Pure LPS-EB for an additional 16 hours. At the end of incubation, culture medium was
collected and the levels of IL-1β and TNF-α released by microglia were assayed using a commercially
available ELISA kits (Antigenix America, Huntington Station, NY, USA), according to the manufacturer's
instructions. Cytokine concentrations (pg/mL) in the medium were determined by reference to standard
curves obtained with known amounts of IL-1β and TNF-α and the results expressed as percentage relative
to LPS-stimulated cultures. Data were analyzed using GraphPad software, version 3.03 (GraphPad Software,
Inc., La Jolla, CA, USA) and expressed as mean ± SEM of at least 3 independent experiments. As raw values
varied between experiments and the variability could obscure the treatment effect, data were expressed as
percentage LPS treatment, taken as baseline of each independent experiment. Data were analyzed by
means of Kruskal-Wallis one-way analysis of variance followed by post-hoc Dunn's test for multiple
comparisons vs LPS treatment. Significance level was set at $p < 0.05$. Additional details are provided in the
figure legends, where appropriate.

Measurement of intracellular ROS. The fluorescent probe 2,7-dichlorodihydrofluorescein diacetate
(DCFH-DA) (Merck KGaA, Darmstadt, Germany) was used as a specific marker for quantitative intracellular

1
2
3 ROS formation. Cells (2×10^4 cells per well) were loaded with 25 μM DCFH-DA for 45 min. After
4 centrifugation DCFH-DA was removed and cells were exposed to 5 and 10 μM of **cur**, compounds **1** and **2**
5 and 300 μM H_2O_2 . ROS levels were determined from 0 to 270 min using Synergy HT multidetection
6 microplate reader (BioTek) with excitation and emission wavelengths of 485 and 530 nm, respectively.
7
8

9
10 **Immunodetection of Nrf2.** The expression of Nrf2 in nuclear cell lysates was assessed using Western blot
11 analysis. Cell monolayers were washed twice with ice-cold PBS, harvested and subsequently homogenized
12 15 times using a glass-glass dounce homogenizer in ice-cold fractionation buffer (20 mM Tris/HCl pH 7.4, 2
13 mM EDTA, 0.5 mM EGTA, 0.32 M sucrose, 50 mM β -mercaptoethanol). The homogenate was centrifuged at
14 300 \times g for 5 min to obtain the nuclear fraction. An aliquot of the nuclear extract was used for protein
15 quantification, whereas the remaining extract was prepared for Western blot by mixing the nuclear cell
16 lysate with 2X sample buffer (125 mM Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 6% β -mercaptoethanol, 0.1%
17 bromophenol blue) and then denaturing at 95 $^\circ\text{C}$ for 5 min. Equivalent amounts of nuclear extracted
18 proteins were loaded into a SDS-PAGE gel, electrophoresed under reducing conditions, transferred to a
19 PVDF membrane (Merck KGaA, Darmstadt Germany) and then blocked for 1 hour with 5% w/v BSA in Tris-
20 buffered saline containing 0.1% Tween 20 (TBS-T). Membranes were immunoblotted with rabbit anti-
21 human Nrf2 (1:2000) diluted in 5% w/v BSA in TBS-T. Detection was carried out by incubation with
22 horseradish peroxidase conjugated goat anti-rabbit IgG (1:5000 dilution in 5% w/v BSA in TBS-T) for 1 hour
23 at room temperature. Membranes were then washed three times with TBS-T and proteins of interest were
24 visualized using an enhanced chemiluminescent reagent (Pierce, Rockford, IL, USA). Lamin A/C was
25 performed as a control for gel loading.
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 SUPPORTING INFORMATION

41
42 Cell viability data, further capillary electrophoresis data, further molecular docking results and steered
43 molecular dynamics data, ^1H NMR spectra, ^{13}C NMR spectra, 2D-COSY spectra.
44
45

46 ABBREVIATIONS

47
48 AD, Alzheimer's disease; $\text{A}\beta$, amyloid-beta; $\text{A}\beta_{42}$, $\text{A}\beta_{1-42}$; CE, capillary electrophoresis; AUC, area under the
49 curve; DMSO, dimethylsulfoxide; cur, curcumin; HFIP, 1,1,1,3,3,3-Hexafluoropropan-2-ol; LPS,
50 lipopolysaccharide; SMD, steered molecular dynamics; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
51 diphenyltetrazolium bromide; ROS, reactive oxygen species; TEM, transmission electron microscopy;
52
53
54
55
56
57
58
59
60

AUTHOR INFORMATION

Corresponding author: Prof. Ersilia De Lorenzi, Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100, Pavia, Italy; tel +39 0382 987747; fax +39 0382 422975; email ersidelo@unipv.it.

Author contributions: **E. De Lorenzi** conceived the project, supervised all contributions and finalized the draft manuscript. **F. Bisceglia** performed CE studies and data analysis, TEM data interpretation, figures and manuscript preparation. **F. Seghetti** synthesized curcumin analogues and performed NMR data. **M. Serra** assisted data analysis and interpretation, the revision of final version of the manuscript and NMR results. **M. Zusso** conceived and carried out the data on microglia, wrote the draft text and prepared the figures of the relative section. **S. Gervasoni** performed molecular modelling studies and assisted data discussion. **L. Verga** performed TEM data and elaborated the relative images. **G. Vistoli** conceived and supervised the molecular modelling studies and wrote the draft of the relative section. **C. Lanni** conceived and supervised the experiments on anti-oxidant activity and cell viability on neuroblastoma cells, wrote the draft of the relative section. **M. Catanzaro** carried out the cell viability experiments on neuroblastoma cells and the data on anti-oxidant activity. **F. Belluti** conceived the design of curcumin analogues, supervised synthesis and NMR characterization, drafted the manuscript.

The authors declare that none of them has competing financial interests in this work.

Funding sources:

University of Padua, Italy (Progetto di Ateneo, grant n. CPDA144389/14 to M.Z.); University of Pavia, Italy (PhD student grant to F.Bi); University of Bologna (PhD student grant to F.S.).

Conflict of interest: The authors declare that none of them has competing financial interests in this work.

ACKNOWLEDGEMENTS

We thank Dr. Luca Regazzoni (University of Milan, Italy) for providing the HRMS data.

REFERENCES

- (1) Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., Fratiglioni, L., Frisoni, G. B., Gauthier, S., Georges, J., Graff, C., Iqbal, K., Jessen, F., Johansson, G., Jonsson, L., Kivipelto, M., Knapp, M., Mangialasche, F., Melis, R., Nordberg, A., Rikkert, M. O., Qiu, C., Sakmar, T. P., Scheltens, P., Schneider, L. S., Sperling, R., Tjernberg, L. O., Waldemar, G., Wimo, A., and Zetterberg, H. (2016) Defeating Alzheimer's disease and other dementias: a priority for European science and society. *Lancet Neurol* *15*, 455-532.
- (2) Chiti, F., and Dobson, C. M. (2017) Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade, *Annu Rev Biochem* *86*, 35.1-35.42.
- (3) Calsolaro, V., and Edison, P. (2016) Neuroinflammation in Alzheimer's disease: Current evidence and future directions. *Alzheimers Dement* *12*, 719-732.
- (4) Querfurth, H. W., and LaFerla, F. M. (2010) Alzheimer's disease, *N Engl J Med* *362*, 329-344.
- (5) Younkin, S. G. (1995) Evidence that A beta 42 is the real culprit in Alzheimer's disease, *Ann Neurol* *37*, 287-288.
- (6) Da Mesquita, S., Ferreira, A. C., Sousa, J. C., Correia-Neves, M., Sousa, N., and Marques, F. (2016) Insights on the pathophysiology of Alzheimer's disease: The crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system, *Neurosci Biobehav Rev* *68*, 547-562.
- (7) Maji, S. K., Ogorzalek Loo, R. R., Inayathullah, M., Spring, S. M., Vollers, S. S., Condrón, M. M., Bitan, G., Loo, J. A., and Teplow, D. B. (2009) Amino acid position-specific contributions to amyloid beta-protein oligomerization, *J Biol Chem* *284*, 23580-23591.
- (8) Liao, M. Q., Tzeng, Y. J., Chang, L. Y., Huang, H. B., Lin, T. H., Chyan, C. L., and Chen, Y. C. (2007) The correlation between neurotoxicity, aggregative ability and secondary structure studied by sequence truncated Abeta peptides. *FEBS Lett* *581*, 1161-1165.
- (9) Tjernberg, L. O., Lilliehook, C., Callaway, D. J., Naslund, J., Hahne, S., Thyberg, J., Terenius, L., and Nordstedt, C. (1997) Controlling amyloid beta-peptide fibril formation with protease-stable ligands, *J Biol Chem* *272*, 12601-12605.
- (10) Belluti, F., Rampa, A., Gobbi, S., and Bisi, A. (2013) Small-molecule inhibitors/modulators of amyloid-beta peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010 - 2012), *Expert Opin Ther Pat* *23*, 581-596.
- (11) Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., and Ashe, K. H. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. *Nat Neurosci* *8*, 79-84.

- 1
2
3 (12) Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe,
4 D. J. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term
5 potentiation in vivo, *Nature* **416**, 535-539.
6
7
8 (13) Benilova, I., Karran, E., and De Strooper, B. (2012) The toxic Abeta oligomer and Alzheimer's disease:
9 an emperor in need of clothes, *Nat Neurosci* **15**, 349-357.
10
11 (14) Lee, S. J., Nam, E., Lee, H. J., Savelieff, M. G., and Lim, M. H. (2017) Towards an understanding of
12 amyloid-beta oligomers: characterization, toxicity mechanisms, and inhibitors, *Chem Soc Rev* **46**, 310-323.
13
14 (15) Leon, R., Garcia, A. G., and Marco-Contelles, J. (2013) Recent advances in the multitarget-directed
15 ligands approach for the treatment of Alzheimer's disease, *Med Res Rev* **33**, 139-189.
16
17 (16) Di Martino, R. M. C., Bisi, A., Rampa, A., Gobbi, S., and Belluti, F. (2017) Recent progress on curcumin-
18 based therapeutics: a patent review (2012-2016). Part II: curcumin derivatives in cancer and
19 neurodegeneration, *Expert Opin Ther Pat* **27**, 953-965.
20
21 (17) Esatbeyoglu, T., Huebbe, P., Ernst, I. M., Chin, D., Wagner, A. E., and Rimbach, G. (2012) Curcumin--
22 from molecule to biological function, *Angew Chem Int Ed Engl* **51**, 5308-5332.
23
24 (18) Prasad, S., Gupta, S. C., Tyagi, A. K., and Aggarwal, B. B. (2014) Curcumin, a component of golden spice:
25 from bedside to bench and back. *Biotechnol Adv* **32**, 1053-1064.
26
27 (19) Masuda, Y., Fukuchi, M., Yatagawa, T., Tada, M., Takeda, K., Irie, K., Akagi, K., Monobe, Y., Imazawa, T.,
28 and Takegoshi, K. (2011) Solid-state NMR analysis of interaction sites of curcumin and 42-residue amyloid
29 beta-protein fibrils, *Bioorg Med Chem* **19**, 5967-5974.
30
31 (20) Zhao, L. N., Chiu, S. W., Benoit, J., Chew, L. Y., and Mu, Y. (2012) The effect of curcumin on the stability
32 of Abeta dimers, *J Phys Chem B* **116**, 7428-7435.
33
34 (21) Orlando, R. A., Gonzales, A. M., Royer, R. E., Deck, L. M., and Vander Jagt, D. L. (2012) A chemical
35 analog of curcumin as an improved inhibitor of amyloid Abeta oligomerization, *PLoS One* **7**, e31869.
36
37 (22) Reinke, A. A., and Gestwicki, J. E. (2007) Structure-activity relationships of amyloid beta-aggregation
38 inhibitors based on curcumin: influence of linker length and flexibility. *Chem Biol Drug Des* **70**, 206-215.
39
40 (23) Nelson, K. M., Dahlin, J. L., Bisson, J., Graham, J., Pauli, G. F., and Walters, M. A. (2017) The Essential
41 Medicinal Chemistry of Curcumin, *J Med Chem* **60**, 1620-1637.
42
43 (24) Baell, J., and Walters, M. A. (2014) Chemistry: Chemical con artists foil drug discovery. *Nature* **513**, 481-
44 483.
45
46 (25) Jasial, S., Hu, Y., and Bajorath, J. (2017) How Frequently Are Pan-Assay Interference Compounds
47 Active? Large-Scale Analysis of Screening Data Reveals Diverse Activity Profiles, Low Global Hit Frequency,
48 and Many Consistently Inactive Compounds, *J Med Chem* **60**, 3879-3886.
49
50 (26) Di Martino, R. M., De Simone, A., Andrisano, V., Bisignano, P., Bisi, A., Gobbi, S., Rampa, A., Fato, R.,
51 Bergamini, C., Perez, D. I., Martinez, A., Bottegoni, G., Cavalli, A., and Belluti, F. (2016) Versatility of the
52
53
54
55
56
57
58
59
60

- 1
2
3 Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3beta Inhibitors, *J Med Chem*
4 59, 531-544.
5
6 (27) Kuzuyama, T., Noel, J. P., and Richard, S. B. (2005) Structural basis for the promiscuous biosynthetic
7 prenylation of aromatic natural products, *Nature* 435, 983-987.
8
9 (28) Brezani, V., Smejkal, K., Hosek, J., and Tomasova, V. (2018) Anti-inflammatory Natural Prenylated
10 Phenolic Compounds - Potential Lead Substances. *Curr Med Chem* 25, 1094-1159.
11
12 (29) Marchiani, A., Rozzo, C., Fadda, A., Delogu, G., and Ruzza, P. (2014) Curcumin and curcumin-like
13 molecules: from spice to drugs. *Curr Med Chem* 21, 204-222.
14
15 (30) Pabon, H. J. J. (1964) A synthesis of curcumin and related compounds. *Recl Trav Chim Pay B* 83, 379-
16 386.
17
18 (31) Mercanti, G., Ragazzi, E., Toffano, G., Giusti, P., and Zusso, M. (2014) Phosphatidylserine and curcumin
19 act synergistically to down-regulate release of interleukin-1beta from lipopolysaccharide-stimulated
20 cortical primary microglial cells, *CNS Neurol Disord Drug Targets* 13, 792-800.
21
22 (32) Bisceglia, F., Natalello, A., Serafini, M. M., Colombo, R., Verga, L., Lanni, C., and De Lorenzi, E. (2018) An
23 integrated strategy to correlate aggregation state, structure and toxicity of Ass 1-42 oligomers. *Talanta* 188,
24 17-26.
25
26 (33) Sabella, S., Quaglia, M., Lanni, C., Racchi, M., Govoni, S., Caccialanza, G., Calligaro, A., Bellotti, V., and
27 De Lorenzi, E. (2004) Capillary electrophoresis studies on the aggregation process of beta-amyloid 1-42 and
28 1-40 peptides, *Electrophoresis* 25, 3186-3194.
29
30 (34) Colombo, R., Carotti, A., Catto, M., Racchi, M., Lanni, C., Verga, L., Caccialanza, G., and De Lorenzi, E.
31 (2009) CE can identify small molecules that selectively target soluble oligomers of amyloid beta protein and
32 display antifibrillogenic activity, *Electrophoresis* 30, 1418-1429.
33
34 (35) Butini, S., Brindisi, M., Brogi, S., Maramai, S., Guarino, E., Panico, A., Saxena, A., Chauhan, V., Colombo,
35 R., Verga, L., De Lorenzi, E., Bartolini, M., Andrisano, V., Novellino, E., Campiani, G., and Gemma, S. (2013)
36 Multifunctional cholinesterase and amyloid Beta fibrillization modulators. Synthesis and biological
37 investigation, *ACS Med Chem Lett* 4, 1178-1182.
38
39 (36) Brinet, D., Gaie-Levrel, F., Delatour, V., Kaffy, J., Ongeri, S., and Taverna, M. (2017) In vitro monitoring
40 of amyloid beta-peptide oligomerization by Electrospray differential mobility analysis: An alternative tool to
41 evaluate Alzheimer's disease drug candidates. *Talanta* 35, 84-91.
42
43 (37) Bartolini, M., Bertucci, C., Bolognesi, M. L., Cavalli, A., Melchiorre, C., and Andrisano, V. (2007) Insight
44 into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of
45 action, *Chembiochem* 8, 2152-2161.
46
47 (38) Hudson, S. A., Ecroyd, H., Kee, T. W., and Carver, J. A. (2009) The thioflavin T fluorescence assay for
48 amyloid fibril detection can be biased by the presence of exogenous compounds. *FEBS J* 279, 5960-5972.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (39) Thapa, A., Jett, S. D., and Chi, E. Y. (2016) Curcumin Attenuates Amyloid-beta Aggregate Toxicity and
4 Modulates Amyloid-beta Aggregation Pathway, *ACS Chem Neurosci* 7, 56-68.
- 5
6 (40) Necula, M., Kaye, R., Milton, S., and Glabe, C. G. (2007) Small molecule inhibitors of aggregation
7 indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct, *J Biol*
8
9 *Chem* 282, 10311-10324.
- 10
11 (41) Zusso, M., Mercanti, G., Belluti, F., Di Martino, R. M. C., Pagetta, A., Marinelli, C., Brun, P., Ragazzi, E.,
12 Lo, R., Stifani, S., Giusti, P., and Moro, S. (2017) Phenolic 1,3-diketones attenuate lipopolysaccharide-
13 induced inflammatory response by an alternative magnesium-mediated mechanism, *Br J Pharmacol* 174,
14 1090-1103.
- 15
16 (42) Baird, L., and Dinkova-Kostova, A. T. (2011) The cytoprotective role of the Keap1-Nrf2 pathway, *Arch*
17 *Toxicol* 85, 241-272.
- 18
19 (43) Ahmed, S. M., Luo, L., Namani, A., Wang, X. J., and Tang, X. (2017) Nrf2 signaling pathway: Pivotal roles
20 in inflammation. *Biochim Biophys Acta* 1863, 585-597.
- 21
22 (44) Pandima Devi, K., Rajavel, T., Daglia, M., Nabavi, S. F., Bishayee, A., and Nabavi, S. M. (2017) Targeting
23 miRNAs by polyphenols: Novel therapeutic strategy for cancer. *Semin Cancer Biol* 46, 146-157.
- 24
25 (45) Liu, Z., Tang, L., Zou, P., Zhang, Y., Wang, Z., Fang, Q., Jiang, L., Chen, G., Xu, Z., Zhang, H., and Liang, G.
26 (2014) Synthesis and biological evaluation of allylated and prenylated mono-carbonyl analogs of curcumin
27 as anti-inflammatory agents, *Eur J Med Chem* 74, 671-682.
- 28
29 (46) Vistoli, G., Colzani, M., Mazzolari, A., Maddis, D. D., Grazioso, G., Pedretti, A., Carini, M., and Aldini, G.
30 (2016) Computational approaches in the rational design of improved carbonyl quenchers: focus on histidine
31 containing dipeptides, *Future Med Chem* 8, 1721-1737.
- 32
33 (47) Rao, P. P., Mohamed, T., Teckwani, K., and Tin, G. (2015) Curcumin Binding to Beta Amyloid: A
34 Computational Study, *Chem Biol Drug Des* 86, 813-820.
- 35
36 (48) Korb, O., Stutzle, T., and Exner, T. E. (2009) Empirical scoring functions for advanced protein-ligand
37 docking with PLANTS. *J Chem Inf Model* 49, 84-96.
- 38
39 (49) Mashiach, E., Schneidman-Duhovny, D., Andrusier, N., Nussinov, R., and Wolfson, H. J. (2008) FireDock:
40 a web server for fast interaction refinement in molecular docking, *Nucleic Acids Res* 36, W229-232.
- 41
42 (50) Vistoli, G., Treumann, A., Zglinicki, T., and Miwa, S. (2016) Data from molecular dynamics simulations in
43 support of the role of human CES1 in the hydrolysis of Amplex Red, *Data Brief* 6, 865-870.
- 44
45 (51) Skaper, S. D., Argentini, C., and Barbierato, M. (2012) Culture of neonatal rodent microglia, astrocytes,
46 and oligodendrocytes from cortex and spinal cord, *Methods Mol Biol* 846, 67-77.
- 47
48
49
50
51
52
53
54
55
56
57
58
59
60






Figure 1. Design strategy toward the curcumin-based analogues **1-4**. Structures of curcumin (**cur**), the newly synthesized curcuminoids (**1**, **2**) and their monocarbonyl analogues (**3**, **4**).

119x50mm (300 x 300 DPI)



Scheme 1. Reagents and conditions: i) B(*n*-BuO)₃; ii) *n*-BuNH₂, 80 °C; iii) HCl, 80 °C; iv) KOH 50%. EtOH, rt.

51x22mm (300 x 300 DPI)



Scheme 2. Reagents and conditions: i) $B(n\text{-BuO})_3$; ii) $n\text{-BuNH}_2$, 80 °C; iii) HCl, 80 °C; iv) KOH 50%. EtOH, rt.

39x13mm (300 x 300 DPI)




Figure 2. Oligomerization of 100 μM A β_{42} in the absence or in the presence of **cur** and of compounds **1-4**. a) Electrophoretic profiles of A β_{42} control (solubilized in 3.26% EtOH in 20 mM phosphate buffer pH 7.4, see Experimental section) at selected elapsed times from t₀ until precipitation: monitoring over time by CE. b) Anti-aggregation activity of 50 μM **cur** and compounds **1-4**: normalized area % of peak 3 at 21 days from sample redissolution as observed in control peptide and in the presence of compounds. Data are expressed as mean \pm standard deviation, for n=3. c-e) Comparison between electrophoretic profiles of 100 μM A β_{42} control (black trace) and in the presence of 10 μM **cur** (green traces), **1** (red traces) and **2** (blue traces) at different elapsed times from redissolution. Electropherograms are representative of n=3.

160x119mm (300 x 300 DPI)





Figure 3. Anti-oligomeric effect of compounds on toxic large oligomers (peak 3) over time. Normalized area percentage plot of peak 3 of 100 μM Aβ₄₂ control and in the presence of decreasing concentrations of: a) **cur**, b) **1**, c) **2**. Data are expressed as mean ± standard deviation, for n=3.

160x106mm (300 x 300 DPI)



20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 4. TEM images of $A\beta_{42}$ control peptide (100 μ M) and 100 μ M $A\beta_{42}$ coincubated with 50 μ M **cur** and **1-4** analyzed at different times from redissolution. Scale bar=100nm. 60000x. n=3

119x50mm (300 x 300 DPI)




Figure 5. Main interactions stabilizing the putative complexes with monomeric A β ₄₂ for a) **cur**, b) **1** and c) **2**, and with the amyloid fibril structure for d) **cur**, e) **1** and f) **2**.

119x79mm (300 x 300 DPI)




Figure 6. Effects of **cur** and analogue **1** on cytokine release from LPS-stimulated cortical microglia cells. a) IL-1 β and b) TNF- α release. Data are mean \pm SEM (standard error of mean) (n=3). * p<0.05, ** p<0.01 and *** p<0.001 vs LPS-stimulated cultures, Kruskal-Wallis followed by post-hoc Dunn's test.

84x59mm (300 x 300 DPI)




Figure 7. Anti-oxidant activity of **cur** and analogues **1** and **2**. a) Reduction of H₂O₂-induced intracellular ROS production: fluorescence intensity for all compounds is significant at any time from 30 to 270 min with $p < 0.001$ vs H₂O₂, with exception of compound **2** at the concentration of 5 μ M. For compound **2** the significance is as follows: $p < 0.05$ at 90 min; $p < 0.01$ at 120 min and 270 min; $p < 0.001$ at 150, 180, 210 and 240 min. Dunnett's multiple comparison test; b) Activation of Nrf2 pathway: SH-SY5H cells were treated for 3 hours with compounds. Results are shown as ratio Nrf2/lamin \pm SEM; * $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$ versus control; Dunnett's multiple comparison test.

99x150mm (300 x 300 DPI)